問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Digestive System Department

National Taiwan University Hospital Yunlin Branch  (在職)

Digestive System Department

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

國立臺灣大學醫學院附設醫院雲林分院

Digestive System Department

更新時間：2023-09-19

劉振驊Liu, Chen-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

11Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉振驊

List

65Cases

2007-12-01 - 2011-07-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-10-01 - 2010-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-11-01 - 2011-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-11-06 - 2023-12-26

Phase II

Completed
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3

  • Condition/Disease

    NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3

  • Test Drug

    PF-06865571PF-05221304

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2020-10-01 - 2025-12-31

Phase II

Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus

  • Condition/Disease

    Patients infected with both hepatitis B and D viruses

  • Test Drug

    JNJ-73763989

Participate Sites
3Sites

Recruiting3Sites

2020-09-01 - 2024-07-05

Phase II

Completed
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Response-guided Treatment With JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog Regimen With or Without Pegylated Interferon Alpha-2a in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection and Normal ALT

  • Condition/Disease

    HBeAg Positive Chronic Hepatitis B Virus Infection

  • Test Drug

    JNJ-56136379JNJ-73763989JNJ-56136379

Participate Sites
4Sites

Recruiting4Sites

2025-12-01 - 2032-08-02

Others

Not yet recruiting
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  • Condition/Disease

    Primary Biliary Cholangitis

  • Test Drug

    Capsules

Participate Sites
7Sites

Not yet recruiting7Sites

2023-02-15 - 2025-06-30

Phase I

Completed
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    注射劑 注射劑

Participate Sites
10Sites

Terminated10Sites

2008-01-15 - 2009-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-11-09 - 2032-11-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB